SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

PSTV (PSTV) News

Follow PSTV (PSTV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol PSTV Asset equity Sector Markets 90 days 1 Last 3.9 Updated Sep 10, 2026, 11:15 AM UTC Open live news feed Open PSTV chart & news
L Cerenome announces up to $20 million financing facility EQUITY | Sep 10, 2026, 11:15 AM UTC L CNSY PSTV - Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and CNSY PSTV - Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines EQUITY | Aug 20, 2026, 11:30 AM UTC L Cerenome reports Q2 2026 financial results and business update Cerenome (PSTV) reports its second quarter 2026 financial results and provides a business update, according to the newsdesk alert. EARNINGS | Aug 14, 2026, 08:15 PM UTC L Cerenome (PSTV) inks HCSC in-network deal, expands CNSide® coverage Cerenome secures an in-network agreement with Health Care Service Corporation, expanding its CNSide® contracted coverage to over 150 million covered lives. MNA | Aug 13, 2026, 11:30 AM UTC H PSTV Launches Cerenome PSTV launches CNS oncology company EQUITY | Jul 31, 2026, 12:30 PM UTC L PSTV - Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference - Click For R PSTV - Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference EQUITY | Jul 28, 2026, 11:30 AM UTC H Plus Therapeutics’ CNSide Diagnostics Signs Regional Agreement With Medical Mutual Covering ~1.2M People Throughout Ohio And Kentucky, To Pr CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) ("Plus" or the "Company"), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026, EARNINGS | Jul 21, 2026, 11:35 AM UTC L PSTV plus Therapeutics and genomic testing cooperative partner to integrate next-generation sequencing into the cnside® csf assay platform PSTV plus Therapeutics and genomic testing cooperative partner to integrate next-generation sequencing into the cnside® csf assay platform EQUITY | Jul 16, 2026, 11:33 AM UTC H Plus Therapeutics Announces Name Change To Cerenome, With Nasdaq Trading Under Symbol 'CNSY,' Effective August 3; Reaffirms FY26 Milestone A Furthermore, the Company affirmed its anticipated 2026 milestones guidance, including commercial guidance around its CNSide Diagnostics business unit. Plus will host a business update conference call and webcast today at EARNINGS | Jun 30, 2026, 11:38 AM UTC M PSTV: Strikes Deal CNSide Diagnostics, a subsidiary of Plus Therapeutics, strikes deal with Elevance Health to offer CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay EQUITY | Jun 25, 2026, 11:35 AM UTC M PSTV Secures Coverage Plus Therapeutics secures national coverage agreement with Elevance Health for CNSide cerebrospinal fluid assay for metastatic CNS cancer EQUITY | Jun 25, 2026, 11:30 AM UTC M PSTV Updates Guidance Plus Therapeutics to provide business update call on June 30, 2026, to discuss mid-year progress and strategy EARNINGS | Jun 23, 2026, 11:31 AM UTC